Fig. 7: Knockdown of CLDN4 significantly inhibits tumor growth in vivo.

A Schematic diagram of targeted therapy in vivo. Xenograft models were established by intracranial injection of luciferase-labeled CLDN4 NC or shCLDN4 U87 (1.5 × 10⁶ cells), which were directly inoculated into the lateral ventricle of nude mice. Mice underwent vivo bioluminescence imaging seven days after implantation, and were implemented the same examination in the next every seven days, IVIS imaging was performed to track tumor progression. ITD-1 or PBS was treated six days after xenotransplantation, and treatment was repeated three times a day. B H&E staining representative images from brain sections of the untreated or treated experimental groups. C Representative cropped bioluminescence images from IVIS imaging showing luminescence of individual mice pictured here over the first 35 days, n ≥ 3 mice per cell type. D Kaplan–Meier curve representing the percent survival of the untreated or treated experimental groups. E IHC representative images of CLDN4 and Ki-67. F Western blotting analysis of the xenograft tumors. (*p, comparing the U87MG NC with the U87MG shCLDN4 + PBS group, ^#p, comparing the U87MG shCLDN4 +PBS with U87MG shCLDN4 +ITD-1, Log-Rank test).